DMSO: The Overlooked “Wonder Solvent” Poised to Transform Eye Disease Treatment
In the high-stakes world of ophthalmology, where vision loss from inflammation, burns, macular degeneration, and diabetic retinopathy devastates millions annually, a quiet revolution may be hiding in plain sight. A landmark 2021 review in the Journal of Ocular Pharmacology and Therapeutics—titled “Application of Dimethyl Sulfoxide as a Therapeutic Agent and Drug Vehicle for Eye Diseases”—makes a compelling case that dimethyl sulfoxide (DMSO), a simple, inexpensive organosulfur compound first synthesized in 1867, could become one of the most versatile tools in modern eye care.
Long dismissed as an industrial solvent or relegated to niche uses like bladder instillation for interstitial cystitis, DMSO is now being spotlighted for its remarkable multi-pronged powers: anti-inflammatory, analgesic, anti-angiogenic, immunomodulatory, and membrane-penetrating. The review, led by Vietnamese ophthalmologist Cuong Hoang and an international team including Ba X. Hoang and Hau D. Tran, synthesizes decades of experimental and clinical data to argue that DMSO deserves a far bigger role in treating acute and chronic ocular disorders.
A Molecule with Superpowers
DMSO’s magic stems from its amphipathic structure—part polar, part nonpolar—allowing it to slip effortlessly through cell membranes and carry other drugs along for the ride. It scavenges free radicals, modulates NF-κB and NLRP3 inflammasome pathways, inhibits angiogenesis by downregulating VEGF and MMP-2, and even boosts the effectiveness of existing antiseptics and anti-inflammatories.
Early human trials dating back to 1968 were astonishing. Gordon and Kleberger applied DMSO (7.5–66%) topically to 157 eyes and reported “favorable clinical results” with zero ocular toxicity observed over 19 months. In the early 1970s, patients with retinitis pigmentosa, macular degeneration, and other retinal diseases experienced stabilized or improved vision, expanded visual fields, and better night vision after corneal immersion in 50% DMSO—results documented with fundus photography showing no tissue damage. Side effects? Mostly transient stinging or a brief garlic-like breath odor from its metabolite.
Animal studies reinforce the human data. In dogs with chronic superficial keratitis (CSK), 50% DMSO combined with low-dose steroids or cyclosporine dramatically outperformed steroids alone, reducing inflammation without harming the corneal epithelium even after 10 months of use. For chemical burns—especially devastating alkali or hydrofluoric acid injuries—DMSO accelerated re-epithelialization, curbed neovascularization, and lowered VEGF expression in rabbit models. One study showed 40% DMSO plus indomethacin healed hydrofluoric acid eye burns far more effectively than indomethacin alone.
Starving Rogue Blood Vessels, Calming Autoimmune Storms
Pathological angiogenesis drives vision loss in diabetic retinopathy, age-related macular degeneration, and retinopathy of prematurity. Current anti-VEGF injections are expensive, require repeated intravitreal needles, and carry risks. DMSO, applied topically as eye drops (up to 40% aqueous solution), suppressed inflammatory cytokines (IL-1, IL-8, leukotrienes), reduced polymorphonuclear cell influx, and blocked endothelial cell tube formation in lab models. In vitro studies even showed it slashed substance P levels (a driver of angiogenesis and metastasis) and boosted interferon-γ.
For inflammatory and autoimmune eye conditions—uveitis, blepharitis, allergic conjunctivitis, scleritis—DMSO’s track record is equally impressive. It has suppressed NF-κB, TNF-α, and other master inflammatory switches in macrophages and whole-blood models. In autoimmune diabetes and graft rejection models, it promoted regulatory T-cell differentiation and prolonged islet graft survival. Combined with povidone-iodine, a DMSO-based gel has shown remarkable success against stubborn blepharitis and demodex infestations—conditions notoriously difficult to treat.
The Ultimate Drug Delivery Vehicle
Perhaps DMSO’s most practical superpower is its ability to solubilize poorly water-soluble drugs and ferry them across ocular barriers. Most topical eye medications achieve only 1–5% corneal penetration. DMSO changes that equation, potentially allowing lower drug doses, fewer side effects, and better outcomes. It already serves as the FDA-approved penetration enhancer in diclofenac topical solution for osteoarthritis and as a 50% intravesical therapy for bladder pain. The review envisions DMSO-enhanced ophthalmic formulations for steroids, antibiotics, antivirals, and even novel biologics—delivered simply as drops or gels.
Safety: The Evidence Is Overwhelming
Critics sometimes raise concerns about toxicity, but the data tell a different story. Extensive toxicology reviews show DMSO is essentially nontoxic by oral, topical, or intravenous routes at therapeutic doses (LD50 in rats exceeds 14 g/kg orally). The most common side effects—mild nausea, transient skin reactions, or garlic breath—are short-lived. Lens changes seen in some high-dose animal studies (50–100 times human therapeutic levels) have never been observed in humans despite decades of use. Intravitreal studies using unrealistically high concentrations caused only transient effects that resolved quickly. In human eye-drop trials with 50% DMSO, patients followed for up to seven years showed minimal visual deterioration and no cataracts.
DMSO is already FDA-approved as a cryoprotectant for stem cells, bone marrow, and sperm, and as an active ingredient in multiple approved products (see Table 2 in the original paper). Newer formulations continue to gain regulatory nods worldwide.
Why Has This Been Ignored?
The authors don’t mince words: DMSO is cheap, non-patentable, and offers little profit motive for pharmaceutical giants. Despite its proven safety and efficacy profile spanning 60+ years, ophthalmologists and developers have largely overlooked it. The review is framed as both a memorial to Dr. Sinh Hoang, who championed better treatments for hard-to-treat eye diseases, and a clarion call for rigorous modern clinical trials.
A Future in Every Drop
Imagine affordable eye drops that simultaneously fight inflammation, starve abnormal blood vessels, accelerate healing from chemical burns or surgery, and supercharge other medications—all with a safety record that dwarfs many current blockbuster drugs. The 2021 review lays out the preclinical and early clinical foundation. What’s missing is large-scale, randomized human trials focused specifically on ocular indications.
As vision-threatening diseases surge globally with aging populations and rising diabetes rates, the scientific community owes it to patients to revisit this “forgotten” molecule. DMSO may never make headlines the way flashy new biologics do—but for millions facing progressive blindness, it could quietly restore sight, reduce suffering, and cut treatment costs dramatically.
The paper’s final message is both humble and urgent: DMSO is safe, effective, and ready. The only question left is whether ophthalmology will finally embrace it.
References and full text available in the Journal of Ocular Pharmacology and Therapeutics (2021). All claims drawn directly from the peer-reviewed literature cited therein.